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TITLE:  
The effect of delayed anti-NMDAR encephalitis recognition on disease outcome 
ABSTRACT: 
Anti-NMDA receptor encephalitis is an acute form of brain inflammation that is potentially lethal but has 
a high probability for recovery with treatment. Although the clinical picture of anti-NMDAR encephalitis 
is usually recognizable due to its relatively well known symptoms the disorder can sometimes present 
itself in an unpredictable and atypical way. In this case report we wish to present the influence of different 
delay times prior to the establishment of diagnosis. Thus, our first patient was diagnosed with anti-
NMDAR encephalitis four years after the initial symptoms, the second one after eight years and the third 
one after thirteen months. The outcomes of the three presented patients indicate the importance of being 
aware of many clinical presentations of this disorder, as its early diagnosis greatly affects the outcome 
and may reduce permanent damage, especially in cognitive functions. 
TEXT:  
Anti-N-Methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterized by 
the presence of specific IgG antibodies against heteromers of NR1 and NR2 subunits of cell-surface NMDA 
receptors which can be found in serum or cerebral spinal fluid (CSF). Although it can be a pure 
autoimmune disorder, anti-NMDAR encephalitis is frequently associated with an underlying malignancy, 
commonly occult ovarian teratoma (Titulaer et al. 2013). The disease symptoms are relatively well known 
and in the majority of cases it usually has a good outcome (Graus at al. 2016; Dalmau et al. 2011). 
However, clinical picture of this multiphasic disorder can sometimes be unpredictable and atypical, 
leading to a delay in the diagnosis establishment. It is usually evident in encephalitis presenting exclusively 
with psychiatric symptoms. The major problem is a lack of the characteristic ones that would imply the 
need for specific antibody testing, which usually leads to prolonged and more demanding treatment with 
increased tendency of worse outcome, cognitive impairment and unpredictable relapses (Herken and 
Pruss 2017; Kayser et al. 2013).  
We are presenting three case reports with different time lapse to diagnosis establishment and 
successfulness of immunosuppression treatment.  
Case report 1 
At the age of seventeen a female patient was admitted to a psychiatry clinic due to psychomotor agitation, 
anxiety, disorganization of thoughts, logorrhea, cognitive impairment, visual and auditory hallucinations 
and insomnia. In spite of initiated antipsychotic therapy (olanzapine, risperidone, quetiapine, clozapine 
and sodium valproate) she developed catatonia and incontinence. Her EEG recording showed 
predominant beta activity, brain MRI was unremarkable, while CSF tests revealed mild pleocytosis (55/3) 
with lymphocyte predomination. On haloperidol and later ziprasidone her psychiatric condition 
ameliorated and for the next four years she was in remission. At the age of twenty-one she developed 
relapse characterized by auditory hallucinations, insomnia, disorganized behavior and psychomotor 
agitation with fever and elevated creatine kinase. Soon after she also developed quantitative disorder of 
consciousness, generalized tonic-clonic seizures that were treated successfully with levetiracetam, 
autonomic dysfunction and respiratory insufficiency. At that point NMDAR antibodies were isolated both 
in serum and CSF. Corticosteroid therapy followed by plasmapheresis was conducted without any 
significant improvement and still in need of mechanical ventilation. The induction of cyclophosphamide 
led to complete symptom resolution and two years after she is still seizure free and without any symptoms 
(mRS 0). 
Case report 2 
Nineteen-year-old patient was admitted to our Department of Neurology due to status epilepticus. Her 
previous medical history revealed frequent hospitalizations in pediatric intensive care unit due to status 
epilepticus, prolonged disorder of consciousness, respiratory insufficiency, autonomic instability with 
sometimes cognitive impairment, language difficulties and associated dyskinesias. In the eight-year-
period she has been hospitalized approximately once a year. Although extensive diagnostic workup was 
conducted, no etiological factor was found. During that period she was treated with corticosteroid therapy 
but there was no clear data of their effectiveness and no other immunosuppressive treatment was 
applied. At the admission to our hospital she was in convulsive status epilepticus with autonomic 
dysfunction and in need of mechanical ventilation. Brain MRI showed unspecific T2 and FLAIR 
hyperintensities (figure 1) and additional workup revealed NMDAR antibodies in serum and CSF. She was 
treated with corticosteroid therapy followed by six cycles of intravenous immunoglobulin and, at last, 
cyclophosphamide, which led to resolution of status epilepticus and other aforementioned symptoms. In 
a four-year period there was no disease relapse, but she still has focal seizures, despite three antiepileptic 
drugs (oxcarbazepine, levetiracetam and clobazam), as well as mild cognitive impairment (mRS 1). 
  
Figure 1. The brain MRI of the patient in second case report showing unspecific T2 and FLAIR 
hyperintensities.  
Case report 3 
Our third patient had focal aware sensory and cognitive (vertiginous sensations, blurring of vision, 
derealisation and depersonalisation) seizures with interictal concentration and behavior changes since 
the age of sixteen. Her brain MRI showed T2 and FLAIR hyperintensity in the left temporal lobe (figure 2), 
CSF pleocytosis, type II oligoclonal bands and left temporal focal EEG changes. After including 
oxcarbazepine in the therapy her seizures were under control as were her psychiatric symptoms. 
Diagnostic workup revealed no etiological factor of her condition. Brain MRI conducted 3 months later 
was without any pathological changes. After eight months her seizures started again, this time with 
evolution to bilateral tonic-clonic convulsions. Repeated brain MRI was unremarkable (figure 3) as was 
EEG recording. CSF analysis was still showing oligoclonal bands type II. In the next few weeks she 
experienced cognitive and psychic deterioration (disorientation in time and space, inadequacy in contact 
without understanding of instructions, she was hostile, had dissociated thoughts with confabulations, 
inadequate answers, difficulties in reconstruction of events, delusions and deterioration of cognitive 
functions). During the two months period large number of typical and atypical antipsychotics were used 
without any improvement. She was then transferred to our Department and corticosteroid therapy was 
started with mild improvement of mental functions, but with persistent epileptic seizures. After proving 
NMDAR antibodies in serum and CSF, intravenous immunoglobulin therapy was started in combination 
with oxcarbazepine, with complete resolution of symptoms (mRS 0). She is without relapse for more than 
one year now. 
 
Figure 2. The brain MRI of the patient in third case report showing T2 and FLAIR hyperintensity in the left 
temporal lobe 
 
Figure 3. The brain MRI of the patient in third case report after eight months. 
In neither of three patients malignancy was found on frequent controls according to Bonn protocol (Bien 
et al. 2007). 
Discussion and conclusion 
In our three patients anti-NMDAR encephalitis was diagnosed one or more years after the initial 
presentation. Symptomatology, disease progression, MRI findings, frequency and time of relapses were 
different in all three cases. The most common cause of prolonged time to diagnosis establishment is 
unawareness of psychiatric symptoms as possible initial presentation of anti-NMDAR encephalitis. It is 
widely known that 77% of patients are initially presented with psychiatric changes (Herken and Pruss 
2017; Dalmau et al. 2008; Barry et al. 2011; Chapman et al. 2011; Lejuste et al. 2016). Psychiatric 
symptoms were initially present in our three patients, being the dominant symptom in the two of them. 
Relapses have been reported in approximately 10-29% of anti-NMDAR encephalitis cases, being more 
common in patients without malignancies, which was also the case in our three patients (Titulaer et al. 
2013; Dalmau et al. 2011; Irani et al. 2011). 
 
Although randomized controlled trials of anti-NMDAR encephalitis therapy are yet to be conducted, large 
retrospective studies suggest that good prognosis, including fewer relapses, is associated with early 
diagnosis and treatment, milder symptoms, and removal of tumor when present (Dalmau et al. 2011; Irani 
et al. 2011; Gabilondo et al. 2011).  In our three cases relapses were present in different time intervals 
without adequate immunosuppressive treatment. The first patient had relapse few years after the initial 
presentation while the other one had disease outbreak before the discovery of specific antibodies. In the 
third case, relapses occurred despite the withdrawal of changes in brain MRI. In all the cases corticosteroid 
therapy was inadequate as a first line of treatment in relapses. The administration of immunoglobulin, 
cyclophosphamid or rituximab was necessary. In correlation with other studies it is possible that early 
administration of immunoglobulin therapy or plasmapheresis could have better results and prevent 
relapses (Titulaer et al. 2013; Gabilondo et al. 2011; Barry et al. 2015; Venkatesan and Adatia 2017). Late 
diagnosis establishment can probably cause permanent damage especially in cognitive functions 
(McKneon et al. 2018; Finke et al. 2018). In spite of delayed diagnosis in our case series, there was no 
permanent cognitive damage in two patients and the third one with frequent relapses had mild cognitive 
impairment and pharmacoresistant seizures. The permanent cognitive damage is probably due to 
repetitive status epilepticus, longer disease duration and more frequent relapses (Sutter et al. 2013; 
Lergiel et al. 2008).  
All three cases had beneficial outcome in spite of delayed diagnostic process which could be due to the 
lack of the underlying malignancy or to a natural history of the disease which can sometimes be benign. 
Nevertheless, the timely diagnosis establishment is of the highest priority, considering that early 
treatment could prevent progression to consciousness impairment, autonomic dysfunction, respiratory 
insufficiency and the need for intensive care unit treatment (de Montmollin et al 2017). 
Anti-NMDAR encephalitis can have different initial presentations, disease course, relapse frequency, 
treatment response and outcome. The recognition of the aforementioned variations can help in timely 
and adequate treatment administration and improve the final outcome of anti-NMDAR encephalitis 
patients. 
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